For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
Revisiting 'The Mother Who Changed: A Story of Dementia'
'The Interview': Charlamagne Tha God Won’t Take Sides
Stormy Daniels Takes The Stand
One Strongman, One Billion Voters, and the Future of India
A Plan to Remake the Middle East
How Changing Ocean Temperatures Could Upend Life on Earth
R.F.K. Jr.’s Battle to Get on the Ballot
Sunday Special: 'Modern Love'
'The Interview': Marlon Wayans Lost Nearly 60 Loved Ones. Comedy Saved Him.
The Protesters and the President
Biden Loosens Up on Weed
The New Abortion Fight Before the Supreme Court
The Secret Push That Could Ban TikTok
Trump 2.0: What a Second Trump Presidency Would Bring
Introducing ‘The Interview’: Yair Lapid Says the World Misunderstands Israel
Introducing ‘The Interview’: Anne Hathaway Is Done Trying to Please
Harvey Weinstein Conviction Thrown Out
The Crackdown on Student Protesters
Is $60 Billion Enough to Save Ukraine?
A Salacious Conspiracy or Just 34 Pieces of Paper?
Create your
podcast in
minutes
It is Free
Up First
Today, Explained
Post Reports
What Next | Daily News and Analysis
The Rachel Maddow Show